INTRODUCTION Interindividual clinical variability is vast in humans infected with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from silent infection to …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR)
doubles with every 5 y of age from childhood onward. Circulating autoantibodies …

Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma
diluted 1: 10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID …

INTRODUCTION Clinical outcomes of human severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection range from silent infection to lethal coronavirus …

Neutralizing autoantibodies against type I interferons (IFNs) have been found in some
patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe …

Life-threatening “breakthrough” cases of critical COVID-19 are attributed to poor or waning
antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting …

Coronavirus disease 2019 (COVID-19) represents a global crisis, yet major knowledge gaps
remain about human immunity to severe acute respiratory syndrome coronavirus 2 (SARS …

Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease
progression that suggest diverse host immune responses. We performed an integrated …

We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19
pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients …

Type‐I interferons (IFNs) mediate antiviral activity and have emerged as important immune
mediators during coronavirus disease 19 (COVID‐19). Several lines of evidence suggest …